Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus

A Double-blind, Randomized, Placebo-controlled, Multicenter Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Systemic Lupus Erythematosus (Sle)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01405196

Acronym

BUTTERFLY

Enrollment

183

Registered

2011-07-29

Start date

2011-12-31

Completion date

2014-03-31

Last updated

2017-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus Erythematosus, Systemic

Keywords

double-blind, placebo-controlled, multicenter, dose-ranging, efficacy, safety, lupus.

Brief summary

The objective of this study is to evaluate and compare efficacy of 3 dose levels of PF-04236921 to placebo in subjects with generalized lupus using a measure called the Systemic Lupus Erythematosus (SLE) Responder Index. The study will evaluate secondary and exploratory measures as well.

Interventions

BIOLOGICALPF-04236921

subcutaneous injection; administered at day 1, weeks 8, 16.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Male or female subjects between ages of 18 and 75 years old at time of signing consent. * Have a clinical diagnosis of SLE according to 1997 update on the revised 1982 American College of Rheumatology (ACR) criteria. * Have a unequivocally positive anti-nuclear antibody (ANA) test result. * Active disease at screening defined by both: SLEDAI-2K score greater than or equal to 6 and BILAG Level A disease in more than or equal to 1 organ system (except renal or central nervous system) or BILAG B disease in more than or equal to 2 organ systems if no level A disease in present.

Exclusion criteria

* Any prior history of treatment with PF-04236921, or anti-IL-6 agent; * Have received any of the following within 364 days of day 1: a biologic investigational agent other than B cell targeted therapy; required 3 or more courses of systemic corticosteroids for concomitant conditions; history of previously untreated or current evidence of active or untreated latent infection with Tuberculosis (TB), evidence of prior untreated or currently active TB by chest radiography, residing with or frequent close contact with an individual with active TB.

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24	Week 24	SRI components include:Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K),British Isles Lupus Assessment Group(BILAG) 2004,Physician's Global Assessment(PhGA).Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: greater than or equal to(\>=) 4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (less than \[\<\] 0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K:assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG:assesses disease extent, severity (range: A\[severe\] to E\[no disease\]). PhGA: assesses worsening in participant's general health status(range: 0\[none\] to 3\[severe\]).

Secondary

Measure	Time frame	Description
Percentage of Participants Achieving Modified Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 4, 8, 12, 16, 20, and 24	Week 4, 8, 12, 16, 20, 24	SRI components include: modified SLEDAI-2K (SLEDAI-2K without standard parameters Low complement and Leukopenia), BILAG 2004, PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: \>=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (\<0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids, immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. Modified SLEDAI-2K: assesses improvement in disease activity (range: 0 to 102; higher score = higher severity). BILAG: assesses disease extent, severity (range: A \[severe\] to E \[no disease\]). PhGA: assesses worsening in participant's general health status (range: 0\[none\] to 3\[severe\]).
Percentage of Participants Achieving British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response at Week 4, 8, 12, 16, 20, and 24	Week 4, 8, 12, 16, 20, 24	BICLA include: BILAG-2004, SLEDAI-2K, PhGA of disease activity. Participants classified as responder if they did not meet the definition of treatment failure and met all the following criteria: BILAG-2004 improvement (all A scores at baseline improved to B/C/D and all B scores improved to C or D); no worsening in disease activity (no new BILAG-2004 A scores or =\<1 new B score); no worsening of total SLEDAI-2K score; no significant deterioration (\<10 percent \[%\] worsening) in analogue PhGA. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. BILAG:assesses disease extent, severity (range: A\[severe\] to E\[no disease\]). SLEDAI-2K:assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). PhGA: assesses worsening in participant's general health status(range: 0\[none\] to 3\[severe\]).
Percentage of Participants Achieving Pre-defined Criteria for Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Components at Week 24	Week 24	SRI components include: SLEDAI-2K, BILAG 2004 and PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: \>=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening(\<0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids, immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K: assesses improvement in disease activity(range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity (range: A\[severe\] to E \[no disease\]). PhGA: assesses worsening in participant's general health status (range: 0\[none\] to 3\[severe\]). Model percent estimates reported only for 'Reduction in SLEDAI Score','No Worsening in PhGA' categories; for remaining categories, raw percentages reported
Number of Participants With Clinically Significant Laboratory Tests Results	Baseline up to Week 52	Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance. Laboratory values included Alanine Aminotransferase (ALT) \[\>5.0 - 10.0\Upper limit of normal range (ULN)\], Albumin \[\<26-20 gram per liter (g/L)/ \<20 g/L\], Amylase \[\>2.0 - 5.0\ULN\], Aspartate Aminotransferase (AST) \[\>5.0 - 10.0\ULN\], Creatine Kinase (CK) \[\>5.0 - 10.0\ ULN/ \>10.0\ULN\], Glucose (Hyperglycemia) \[\>13.9 - 27.8 millimoles/liter (mmol/L)\], Hemoglobin (HGB) \[\<80 - 65 g/L/ \<65 g/L\], Lipase \[\>2.0 - 5.0\ULN\], Lymphocytes (Lymph.)(Absolute \[Abs\]) \[\<0.5 - 0.2\10\^3/microliter (UL)/ \<0.2\10\^3/UL\], Platelets \[\<50-25\10\^3/UL/ \<25\10\^3/UL\], potassium (low) \[\<3.0 - 2.5 mmol/L\], Sodium (low) \[\<130 - 120 mmol/L\], Total Neutrophils (TN) (Abs) \[\<1.0 - 0.5\10\^3/UL/ \<0.5\10\^3/UL\], Triglycerides \[\>5.7 - 11.4 mmol/L\], White Blood Cell Count (WBC) \[\<2.0 - 1.0\10\^3/UL/ \<1.0\10\^3/UL\].
Number of Participants Who Discontinued Due to Adverse Events	Baseline up to Week 52	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Number of participants who discontinued due to adverse events were reported.
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)	Baseline up to Week 52	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 52 that were absent before treatment or that worsened relative to pretreatment state. Number of participants with treatment-emergent AEs or SAEs (excluding infectious AEs or SAEs and injection site reactions) were reported. AEs include both SAEs and non-SAEs.
Number of Participants With Treatment-Emergent Infectious Adverse Events (AEs) or Serious Adverse Events (SAEs)	Baseline up to Week 52	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 52 that were absent before treatment or that worsened relative to pretreatment state. Number of participants with treatment-emergent infectious AEs or SAEs were reported. AEs include both SAEs and non-SAEs.
Number of Participants With Potentially Clinically Important (PCI) Electrocardiogram (ECG) Findings	Baseline up to Week 52	Criteria for potentially clinically important (PCI) findings in ECG were defined as: heart rate \<=40 beats per minute (bpm) or \>=120 bpm; PR interval \>=220 millisecond (msec); QT interval \>=480 msec; QRS interval \>=120 msec; QT interval corrected using the Fridericia formula (QTcF) \>=500msec; no sinus rhythm.
Number of Participants With Potentially Clinically Important Vital Signs Findings	Baseline up to Week 52	Criteria for PCI findings in vital signs were defined as: sitting systolic blood pressure (Increase from baseline \>=20 millimeter of mercury (mm Hg) and \>=160 mm Hg or a decrease from baseline \>=20 mm Hg and \<=90 mm Hg) and sitting diastolic blood pressure (increase from baseline \>=15 mm Hg and \>=90 mm Hg or decrease from baseline \>=15 mm Hg and \<=60 mm Hg), pulse rate (increase from baseline \>=15 beats/min and \>=120 beats/min or decrease from baseline \>=15 beats/min and \<=50 beats /min), body temperature (increase of \>=2 degree Fahrenheit (F) and temperature \>=101 degree F) and weight (change of \>=7% in body weight)
Number of Participants With Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (Nabs)	Baseline up to Week 52	Human serum samples were analyzed for the presence or absence of anti-PF-04236921 antibodies. A positive ADA sample was further tested for neutralizing antibodies using a validated assay.
Serum Concentration of PF-04236921	Day 1, Week 2, 4, 6, 8, 12, 16, 20, 24	Serum PF-04236921 concentrations over time were summarized.
Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 4, 8, 12, 16, and 20	Week 4, 8, 12, 16, 20	SRI components include:SLEDAI-2K ,BILAG 2004, PhGA. Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: \>=4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (\<0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG:assesses disease extent, severity (range: A \[severe\] to E \[no disease\]). PhGA: assesses worsening in participant's general health status(range: 0\[none\] to 3\[severe\]).
Percentage of Participants With Normalized Serological Activity	Baseline up to Week 24	Serologic activity was to be assessed in the subgroup of participants who had positive serologic activity at baseline.
Patient Global Visual Analog Scale (VAS) Scores at Baseline	Baseline	Participants assessed their disease activity using a 100 millimeter (mm) VAS. Participants answered the following question Considering all the ways your disease affects you, how are you feeling today? Response was recorded by placing a mark on the scale between 0 (very well) and 100 (extremely bad).
Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24	Participants assessed their disease activity using a 100 mm VAS. Participants answered the following question Considering all the ways your disease affects you, how are you feeling today? Response was recorded by placing a mark on the scale between 0 (very well) and 100 (extremely bad).
Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Baseline, Week 4, 8, 12, 16, 20, 24	EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point VAS (0= worst imaginable health state, 100= best imaginable health state).
Thirty Six-Item Short-Form Health Survey (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) at Baseline	Baseline	SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as PCS and mental component score MCS. The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	Baseline, Week 4, 8, 12, 16, 20, 24	SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical component score (PCS) and mental component score (MCS). The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.
Change From Baseline in Vitality Scores at Week 4, 8, 12, 16, 20 and 24	Baseline, Week 4, 8, 12, 16, 20, 24	SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Vitality sub-score is a component of SF-36 Health Survey Questionnaire and assesses energy and fatigue. The vitality score ranged from 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.
Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	Baseline, Week 4, 8, 12, 16, 20, 24	The SF-6D focuses on seven of the eight health domains covered by the SF-36 Health Survey: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. The SF-6D is an attempt to derive a single index from the SF-36 Health Survey for use in economic evaluation studies. As such, it represents a summary score based on a subset of the SF-36 data. Consequently, in lieu of the SF-6D, PCS and MCS SF-36 results are being provided. The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Baseline	Baseline	FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Baseline, Week 4, 8, 12, 16, 20, 24	FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). LOCF method was used to impute missing values.
Percentage of Participants With Corticosteroid Dose Reduced by Both Greater Than or Equal to (>=) 25 Percent (%) From Baseline and Less Than or Equal to (<=) 7.5 Milligrams Per Day (mg/Day)	Week 12, 16, 20, 24	Participants were given supplemental corticosteroids at baseline to control disease activity, if necessary. The steroid taper was based on participant's symptoms. Participants recorded their steroid usage on a diary card. Least Observation Carried Forward (LOCF) method was used to impute missing data.

Countries

Argentina, Chile, Colombia, Germany, Hungary, Moldova, Peru, Poland, Puerto Rico, Romania, South Korea, Taiwan, United States

Participant flow

Pre-assignment details

Due to safety reason, dosing in 200 mg reporting arm was prematurely terminated and the participants were discontinued from it. Therefore, the statistical analysis plan was amended after it and 200 mg reporting arm was not included in efficacy data analysis.

Participants by arm

Arm	Count
PF-04236921 10 Milligram (10 mg) Participants received 10 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.	45
PF-04236921 50 mg Participants received 50 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.	47
PF-04236921 200 mg Participants received 200 mg dose of PF-04236921 subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.	46
Placebo Placebo matching to PF-04236921 administered subcutaneously in the anterolateral right and left thighs at Week 0, Week 8 and Week 16.	45
Total	183

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Overall Study	Adverse Event	2	2	0	2
Overall Study	Death	1	0	3	0
Overall Study	Lost to Follow-up	2	2	3	1
Overall Study	Other	2	2	5	0
Overall Study	Study Terminated by Sponsor	0	0	9	0
Overall Study	Withdrawal by Subject	4	6	3	6

Baseline characteristics

Characteristic	PF-04236921 10 Milligram (10 mg)	PF-04236921 50 mg	PF-04236921 200 mg	Placebo	Total
Age, Continuous	39.9 Years STANDARD_DEVIATION 11.48	38.3 Years STANDARD_DEVIATION 10.49	41.3 Years STANDARD_DEVIATION 11.29	42.3 Years STANDARD_DEVIATION 13.04	40.4 Years STANDARD_DEVIATION 11.6
Sex: Female, Male Female	43 Participants	44 Participants	43 Participants	38 Participants	168 Participants
Sex: Female, Male Male	2 Participants	3 Participants	3 Participants	7 Participants	15 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —
other Total, other adverse events	20 / 45	24 / 47	32 / 46	26 / 45
serious Total, serious adverse events	4 / 45	3 / 47	7 / 46	8 / 45

Outcome results

Primary

Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24

SRI components include:Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K),British Isles Lupus Assessment Group(BILAG) 2004,Physician's Global Assessment(PhGA).Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: greater than or equal to(\>=) 4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (less than \[\<\] 0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K:assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG:assesses disease extent, severity (range: A\[severe\] to E\[no disease\]). PhGA: assesses worsening in participant's general health status(range: 0\[none\] to 3\[severe\]).

Time frame: Week 24

Population: Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Number of participants analyzed= participants who completed through the Week 24 visit. As per sponsor's decision, dosing in PF-04236921 200 mg arm was prematurely terminated and hence it was not included in efficacy analysis.

Arm	Measure	Value (NUMBER)
PF-04236921 10 Milligram (10 mg)	Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24	59.9 Percentage of participants
PF-04236921 50 mg	Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24	39.2 Percentage of participants
Placebo	Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24	40.1 Percentage of participants

Comparison: Point estimates of the Odds ratio (ORs) as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.p-value: 0.07690% CI: [0.89, 5.62]Mixed Models Analysis

Comparison: Point estimates of the ORs as well as their confidence intervals were calculated from the generalized linear mix model that included fixed factors of the stratification factors, treatment, visit and treatment by visit.p-value: 0.52890% CI: [0.38, 2.41]Mixed Models Analysis

Secondary

Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24

SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical component score (PCS) and mental component score (MCS). The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.

Time frame: Baseline, Week 4, 8, 12, 16, 20, 24

Population: Full Analysis Set= all randomized participants who received at least 1 dose of study drug. Here, number analyzed signifies those participants who were evaluable at specified time points. As per sponsor's decision, dosing in PF-04236921 200 mg arm was prematurely terminated and hence it was not included in efficacy analysis.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 16	4.73 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 4	1.97 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 8	1.57 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 12	3.80 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 20	4.49 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 24	2.94 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 4	3.95 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 8	5.48 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 12	6.06 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 16	6.25 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 20	6.39 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 24	5.98 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 24	5.53 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 12	4.66 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 4	1.45 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 4	3.24 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 24	2.14 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 8	1.97 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 20	5.63 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 8	4.79 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 12	2.50 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 20	1.71 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 16	2.79 Units on a scale
PF-04236921 50 mg	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 16	4.50 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 16	2.95 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 20	3.28 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 16	2.48 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 24	2.85 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 4	1.28 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 8	2.11 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 20	3.29 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 4	1.45 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 12	2.82 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 8	2.05 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	PCS: Week 24	2.94 Units on a scale
Placebo	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) PCS and MCS at Week 4, 8, 12, 16, 20 and 24	MCS: Week 12	2.52 Units on a scale

Comparison: MCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-2.53, 3.59]

Comparison: MCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-3.54, 2.58]

Comparison: MCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-1.78, 4.34]

Comparison: MCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-1.28, 4.84]

Comparison: MCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-1.86, 4.26]

Comparison: MCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-2.98, 3.15]

Comparison: MCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-3.03, 3.03]

Comparison: MCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-3.09, 2.92]

Comparison: MCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-3.03, 2.99]

Comparison: MCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-3.17, 2.85]

Comparison: MCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-4.58, 1.43]

Comparison: MCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-3.72, 2.3]

Comparison: PCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [0.14, 5.2]

Comparison: PCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [0.84, 5.89]

Comparison: PCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [0.7, 5.76]

Comparison: PCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [1.24, 6.3]

Comparison: PCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [0.57, 5.63]

Comparison: PCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [0.5, 5.56]

Comparison: PCS Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-0.53, 4.46]

Comparison: PCS Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [0.2, 5.17]

Comparison: PCS Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-0.65, 4.32]

Comparison: PCS Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-0.47, 4.5]

Comparison: PCS Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-0.15, 4.82]

Comparison: PCS Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [0.11, 5.08]

Secondary

Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24

EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point VAS (0= worst imaginable health state, 100= best imaginable health state).

Time frame: Baseline, Week 4, 8, 12, 16, 20, 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
PF-04236921 10 Milligram (10 mg)	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 20	9.68 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 12	7.47 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 16	6.84 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 24	9.33 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 8	5.00 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 4	3.17 Units on a scale
PF-04236921 50 mg	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 12	2.51 Units on a scale
PF-04236921 50 mg	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 4	1.45 Units on a scale
PF-04236921 50 mg	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 8	2.82 Units on a scale
PF-04236921 50 mg	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 16	6.65 Units on a scale
PF-04236921 50 mg	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 20	5.19 Units on a scale
PF-04236921 50 mg	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 24	5.04 Units on a scale
Placebo	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 8	7.02 Units on a scale
Placebo	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 24	5.38 Units on a scale
Placebo	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 20	5.09 Units on a scale
Placebo	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 12	4.85 Units on a scale
Placebo	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 4	-0.47 Units on a scale
Placebo	Change From Baseline in European Quality of Life 5 Dimensions Questionnaire (EQ-5D) at Week 4, 8, 12, 16, 20 and 24	Week 16	5.16 Units on a scale

Comparison: Week 4: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.90% CI: [-2.56, 9.83]

Comparison: Week 8: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.90% CI: [-8.21, 4.18]

Comparison: Week 12: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.90% CI: [-3.57, 8.82]

Comparison: Week 16: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.90% CI: [-4.51, 7.88]

Comparison: Week 20: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.90% CI: [-1.61, 10.79]

Comparison: Week 24: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline tender score.90% CI: [-2.24, 10.15]

Secondary

Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24

FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). LOCF method was used to impute missing values.

Time frame: Baseline, Week 4, 8, 12, 16, 20, 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 4	3.16 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 8	4.39 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 12	5.07 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 16	5.81 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 20	5.37 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 24	4.39 Units on a scale
PF-04236921 50 mg	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 24	3.30 Units on a scale
PF-04236921 50 mg	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 4	2.77 Units on a scale
PF-04236921 50 mg	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 16	5.53 Units on a scale
PF-04236921 50 mg	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 20	4.32 Units on a scale
PF-04236921 50 mg	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 8	3.41 Units on a scale
PF-04236921 50 mg	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 12	3.59 Units on a scale
Placebo	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 8	2.44 Units on a scale
Placebo	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 12	2.26 Units on a scale
Placebo	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 24	2.70 Units on a scale
Placebo	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 16	1.93 Units on a scale
Placebo	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 4	1.08 Units on a scale
Placebo	Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 4, 8, 12, 16, 20 and 24	Week 20	3.42 Units on a scale

Comparison: Week 4: Analysis was done using the ANCOVA model; CI parameter being the Least Square (LS) mean difference from that model.90% CI: [-1.26, 5.42]

Comparison: Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-1.38, 5.29]

Comparison: Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-0.53, 6.15]

Comparison: Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [0.54, 7.22]

Comparison: Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-1.39, 5.29]

Comparison: Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-1.65, 5.03]

Comparison: Week 4: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-1.61, 4.99]

Comparison: Week 8: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-2.31, 4.26]

Comparison: Week 12: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-1.96, 4.61]

Comparison: Week 16: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [0.32, 6.89]

Comparison: Week 20: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-2.38, 4.19]

Comparison: Week 24: Analysis was done using the ANCOVA model; CI parameter being the LS mean difference from that model.90% CI: [-2.68, 3.88]

Secondary

Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24

Participants assessed their disease activity using a 100 mm VAS. Participants answered the following question Considering all the ways your disease affects you, how are you feeling today? Response was recorded by placing a mark on the scale between 0 (very well) and 100 (extremely bad).

Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 2	-9.17 mm
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 4	-3.24 mm
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 6	-5.48 mm
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 8	-4.17 mm
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 12	-9.21 mm
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 16	-8.75 mm
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 20	-11.52 mm
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 24	-9.17 mm
PF-04236921 50 mg	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 6	-3.62 mm
PF-04236921 50 mg	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 20	-9.03 mm
PF-04236921 50 mg	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 8	-6.03 mm
PF-04236921 50 mg	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 12	-4.20 mm
PF-04236921 50 mg	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 16	-10.20 mm
PF-04236921 50 mg	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 2	-1.54 mm
PF-04236921 50 mg	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 4	-4.01 mm
PF-04236921 50 mg	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 24	-7.45 mm
Placebo	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 6	-7.24 mm
Placebo	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 4	-1.24 mm
Placebo	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 2	-3.58 mm
Placebo	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 8	-7.11 mm
Placebo	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 20	-6.77 mm
Placebo	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 16	-5.99 mm
Placebo	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 12	-6.88 mm
Placebo	Change From Baseline in Patient Global Visual Analog Scale (VAS) at Week 2, 4, 6, 8, 12, 16, 20 and 24	Week 24	-10.64 mm

Comparison: Week 2: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.90% CI: [-12.3, 1.49]

Comparison: Week 6: Analysis was done using linear mixed effect model that included fixed factors of the stratification factors, treatment, visit, treatment by visit and baseline VAS.90% CI: [-5.71, 8.32]

Secondary

Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24

The SF-6D focuses on seven of the eight health domains covered by the SF-36 Health Survey: physical functioning, role participation (combined role-physical and role-emotional), social functioning, bodily pain, mental health, and vitality. The SF-6D is an attempt to derive a single index from the SF-36 Health Survey for use in economic evaluation studies. As such, it represents a summary score based on a subset of the SF-36 data. Consequently, in lieu of the SF-6D, PCS and MCS SF-36 results are being provided. The score for each aspect and PCS/MCS is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). LOCF method was used to impute missing values.

Time frame: Baseline, Week 4, 8, 12, 16, 20, 24

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 4	1.97 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 8	1.57 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 12	3.80 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 16	4.73 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 20	4.49 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 24	2.94 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 4	3.95 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 8	5.48 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 12	6.06 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 16	6.25 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 20	6.39 Units on a scale
PF-04236921 10 Milligram (10 mg)	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 24	5.98 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 24	5.53 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 4	1.45 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 4	3.24 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 12	4.66 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 8	1.97 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 24	2.14 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 20	5.63 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 12	2.50 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 8	4.79 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 20	1.71 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 16	2.79 Units on a scale
PF-04236921 50 mg	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 16	4.50 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 16	2.95 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 20	3.28 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 16	2.48 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 24	2.85 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 4	1.28 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 8	2.11 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 20	3.29 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 4	1.45 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 8	2.05 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 12	2.82 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	MCS: Week 12	2.52 Units on a scale
Placebo	Change From Baseline in Short Form-6 Dimension (SF-6D) at Week 4, 8, 12, 16, 20 and 24	PCS: Week 24	2.94 Units on a scale